- Record: found
- Abstract: found
- Article: not found
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D Pavord
1 ,
Stephanie Korn ,
Peter Howarth ,
Eugene R Bleecker ,
Roland Buhl ,
Oliver N Keene ,
Hector Ortega ,
Pascal Chanez
Aug 18 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab.